426 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
SNY Sanofi $43.75 $109.14B Downtrend
Article Searches
Alphabet Halts Glucose Lens Work to Focus on Other Projects http://www.zacks.com/stock/news/338339/alphabet-halts-glucose-lens-work-to-focus-on-other-projects?cid=CS-ZC-FT-338339 Nov 19, 2018 - Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug http://www.zacks.com/stock/news/336619/pharma-stock-roundup-lly-azn-report-q3-earnings-pfe-gets-fda-nod-for-cancer-drug?cid=CS-ZC-FT-336619 Nov 09, 2018 - Lilly (LLY) and AstraZeneca (AZN) report third-quarter results. Pfizer (PFE) gains FDA approval for a new cancer medicine.
Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review http://www.zacks.com/stock/news/335894/sanofi-eczema-drug-dupixents-sbla-gets-priority-review?cid=CS-ZC-FT-335894 Nov 07, 2018 - Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line http://www.zacks.com/stock/news/335611/regeneron-regn-q3-earnings-beat-estimates-revenues-in-line?cid=CS-ZC-FT-335611 Nov 06, 2018 - Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO http://www.zacks.com/stock/news/334797/drug-stocks-to-post-earnings-on-nov-5-myl-nbix-rare-taro?cid=CS-ZC-FT-334797 Nov 02, 2018 - We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates http://www.zacks.com/stock/news/334819/emergent-ebs-q3-earnings-and-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-334819 Nov 02, 2018 - Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus http://www.zacks.com/stock/news/334564/pharma-stock-roundup-pfe-agn-q3-earnings-lly-nvs-collaboration-deals-in-focus?cid=CS-ZC-FT-334564 Nov 02, 2018 - Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store? http://www.zacks.com/stock/news/334453/regeneron-regn-to-report-q3-earnings-is-a-beat-in-store?cid=CS-ZC-FT-334453 Nov 01, 2018 - Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) third-quarter earnings call.
SNY: Barclays ups to Equal Weight http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20181101070530 Nov 01, 2018 - Barclays issues rating change for SNY
Sanofi (SNY) Q3 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2018/10/31/sanofi-sny-q3-2018-earnings-conference-call-transc.aspx?source=iedfolrf0000001 Oct 31, 2018 - SNY earnings call for the period ending September 30, 2018.

Pages: 1234567891011...43

<<<Page 6>